Filippo Bellati

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3370963/publications.pdf

Version: 2024-02-01

all docs

		136950	182427	
106	3,107	32	51	
papers	citations	h-index	g-index	
				_
109	109	109	3508	

times ranked

docs citations

citing authors

#	Article	IF	CITATIONS
1	Adjuvant vaginal interventional radiotherapy in early-stage non-endometrioid carcinoma of corpus uteri: aÂsystematic review. Journal of Contemporary Brachytherapy, 2021, 13, 231-243.	0.9	2
2	The Clinical and Pathological Profile of BRCA1 Gene Methylated Breast Cancer Women: A Meta-Analysis. Cancers, 2021, 13, 1391.	3.7	9
3	Fibrin Sealants and Axillary Lymphatic Morbidity: A Systematic Review and Meta-Analysis of 23 Clinical Randomized Trials. Cancers, 2021, 13, 2056.	3.7	4
4	Effects of Endocrine-Disrupting Chemicals on Endometrial Receptivity and Embryo Implantation: A Systematic Review of 34 Mouse Model Studies. International Journal of Environmental Research and Public Health, 2021, 18, 6840.	2.6	19
5	Biological Impact of Unilateral Oophorectomy: Does the Number of Ovaries Really Matter?. Geburtshilfe Und Frauenheilkunde, 2021, 81, 331-338.	1.8	9
6	Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials. Cancer Treatment Reviews, 2020, 87, 102040.	7.7	35
7	The role of vaginal brachytherapy in stage I endometrial serous cancer: a systematic review. Journal of Contemporary Brachytherapy, 2020, 12, 61-66.	0.9	10
8	Bevacizumab-Based Chemotherapy Triggers Immunological Effects in Responding Multi-Treated Recurrent Ovarian Cancer Patients by Favoring the Recruitment of Effector T Cell Subsets. Journal of Clinical Medicine, 2019, 8, 380.	2.4	25
9	Low endometrial beta-catenin and cadherins expression patterns are predictive for primary infertility and recurrent pregnancy loss. Gynecological Endocrinology, 2019, 35, 727-731.	1.7	13
10	Neoantigens from the bench to the bedside: new prospective for ovarian cancer immunotherapy. Annals of Translational Medicine, 2019, 7, S305-S305.	1.7	2
11	The prognostic impact of cancer stem-like cell biomarker aldehyde dehydrogenase-1 (ALDH1) in ovarian cancer: A meta-analysis. Gynecologic Oncology, 2018, 150, 151-157.	1.4	21
12	Endocrine Disrupting Chemicals and Endometrial Cancer: An Overview of Recent Laboratory Evidence and Epidemiological Studies. International Journal of Environmental Research and Public Health, 2017, 14, 334.	2.6	71
13	Tumor-Derived Microvesicles Modulate Antigen Cross-Processing via Reactive Oxygen Species-Mediated Alkalinization of Phagosomal Compartment in Dendritic Cells. Frontiers in Immunology, 2017, 8, 1179.	4.8	21
14	Sentinel Node Mapping in Cervical and Endometrial Cancer: Indocyanine Green Versus Other Conventional Dyes—A Meta-Analysis. Annals of Surgical Oncology, 2016, 23, 3749-3756.	1.5	150
15	Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I/II clinical trial. International Journal of Oncology, 2016, 48, 1369-1378.	3.3	28
16	Circulating tumor cells as trigger to hematogenous spreads and potential biomarkers to predict the prognosis in ovarian cancer. Tumor Biology, 2016, 37, 71-75.	1.8	25
17	Immunological and Clinical Impact of Cancer Stem Cells in Vulvar Cancer: Role of CD133/CD24/ABCG2-Expressing Cells. Anticancer Research, 2016, 36, 5109-5116.	1.1	11
18	Thrombotic thrombocytopenic purpura during pregnancy versus imitator of preeclampsia. Transfusion, 2015, 55, 2516-2518.	1.6	6

#	Article	IF	CITATIONS
19	The Macrophage Galactose-Type C-Type Lectin (MGL) Modulates Regulatory T Cell Functions. PLoS ONE, 2015, 10, e0132617.	2.5	35
20	Surgical Treatment of Recurrent Endometrial Cancer: Time for a Paradigm Shift. Annals of Surgical Oncology, 2015, 22, 4204-4210.	1.5	41
21	When Does Neoadjuvant Chemotherapy Really Avoid Radiotherapy? Clinical Predictors of Adjuvant Radiotherapy in Cervical Cancer. Annals of Surgical Oncology, 2015, 22, 944-951.	1.5	13
22	Microvesicle Cargo of Tumor-Associated MUC1 to Dendritic Cells Allows Cross-presentation and Specific Carbohydrate Processing. Cancer Immunology Research, 2014, 2, 177-186.	3.4	23
23	Effects of unilateral ovariectomy on female fertility outcome. Archives of Gynecology and Obstetrics, 2014, 290, 349-353.	1.7	26
24	Discovery of chemotherapy-associated ovarian cancer antigens by interrogating memory T cells. International Journal of Cancer, 2014, 134, 1823-1834.	5.1	19
25	Gene Expression Profile of Patients with Mayer-Rokitansky-Kýster-Hauser Syndrome: New Insights into the Potential Role of Developmental Pathways. PLoS ONE, 2014, 9, e91010.	2.5	29
26	Surgical treatment of an isolated omental cervical cancer recurrence: report of a case and review of the literature. Tumori, 2014, 100, e52-4.	1.1	0
27	Minimal invasive approaches for large ovarian cysts: a careful choice. Archives of Gynecology and Obstetrics, 2013, 287, 615-616.	1.7	1
28	CO2 Laser Treatment for Bartholin Gland Abscess: Ultrasound Evaluation of Risk Recurrence. Journal of Minimally Invasive Gynecology, 2013, 20, 346-352.	0.6	6
29	Interaction between treg cells and angiogenesis: A dark double track. International Journal of Cancer, 2013, 132, 2469-2469.	5.1	6
30	Monoclonal antibodies therapies for ovarian cancer. Expert Opinion on Biological Therapy, 2013, 13, 739-764.	3.1	21
31	Chemotherapy in Elderly Patients with Gynecological Cancer. Oncology, 2013, 85, 168-172.	1.9	14
32	Intraperitoneal Chemotherapy by Ultrasound-Guided Direct Puncture in Recurrent Ovarian Cancer: Feasibility, Compliance, and Complications. International Journal of Gynecological Cancer, 2012, 22, 1069-1074.	2.5	11
33	Thinking twice before abandoning first-line chemotherapy in ovarian cancer: report of two cases and literature review. Passing from tri-weekly to weekly regimens. International Journal of Clinical Oncology, 2012, 17, 385-389.	2.2	1
34	Laparoscopically guided minilaparotomy: a minimally invasive approach for the treatment of gynaecologic diseases in morbidly obese patients. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2012, 160, 210-214.	1.1	3
35	First case of isolated vaginal metastasis from breast cancer treated by surgery. BMC Cancer, 2012, 12, 479.	2.6	6
36	Olaparib, PARP1 inhibitor in ovarian cancer. Expert Opinion on Investigational Drugs, 2012, 21, 1575-1584.	4.1	30

3

#	Article	IF	CITATIONS
37	Response criteria can be misleading when drawing conclusion regarding neoadjuvant chemotherapy in advanced ovarian cancer. Journal of Surgical Oncology, 2012, 106, 529-529.	1.7	2
38	Targeting of macrophage galactoseâ€type <scp>C</scp> â€type lectin (<scp>MGL</scp>) induces <scp>DC</scp> signaling and activation. European Journal of Immunology, 2012, 42, 936-945.	2.9	84
39	Vaginal cancer. Critical Reviews in Oncology/Hematology, 2012, 81, 286-295.	4.4	74
40	Role of chemotherapy in the management of vulvar carcinoma. Critical Reviews in Oncology/Hematology, 2012, 82, 25-39.	4.4	19
41	Current knowledge and open issues regarding Bevacizumab in gynaecological neoplasms. Critical Reviews in Oncology/Hematology, 2012, 83, 35-46.	4.4	27
42	Simple extrafascial trachelectomy and pelvic bilateral lymphadenectomy in early stage cervical cancer. Gynecologic Oncology, 2012, 126, 78-81.	1.4	44
43	The web as a snack. Preventive Medicine, 2012, 54, 286.	3.4	0
44	BRCA1 methylation status in high-grade serous ovarian cancer (HGSOC) patients (pts) Journal of Clinical Oncology, 2012, 30, 5070-5070.	1.6	0
45	Oral Estroprogestins after Laparoscopic Surgery to Excise Endometriomas: Continuous or Cyclic Administration? Results of a Multicenter Randomized Study. Journal of Minimally Invasive Gynecology, 2011, 18, 173-178.	0.6	32
46	Invasive vulvar carcinoma and the question of the surgical margin. International Journal of Gynecology and Obstetrics, 2011, 114, 120-123.	2.3	21
47	Immune Effects of Trastuzumab. Journal of Cancer, 2011, 2, 317-323.	2.5	35
48	Feasibility and safety of type C2 total extraperitoneal abdominal radical hysterectomy (TEARH) for locally advanced cervical cancer. Gynecologic Oncology, 2011, 120, 423-429.	1.4	5
49	Is There a Real Standard For Stage IVa Cervical Cancer?. Gynecologic Oncology, 2011, 123, 174-175.	1.4	5
50	HER2-based recombinant immunogen to target DCs through FcγRs for cancer immunotherapy. Journal of Molecular Medicine, 2011, 89, 1231-1240.	3.9	12
51	Vaginal Reconstruction with the Abb \tilde{A}^{\cdot} -McIndoe Technique: From Dermal Grafts to Autologous in Vitro Cultured Vaginal Tissue Transplant. Seminars in Reproductive Medicine, 2011, 29, 045-054.	1.1	25
52	Monoclonal Antibodies in Gynecological Cancer: A Critical Point of View. Clinical and Developmental Immunology, 2011, 2011, 1-16.	3.3	38
53	Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review. Investigational New Drugs, 2010, 28, 887-894.	2.6	44
54	Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression. Journal of Cellular and Molecular Medicine, 2010, 14, 2748-2759.	3.6	61

#	Article	IF	CITATIONS
55	Immunologic Systemic Effect of Neoadjuvant Chemotherapy Requires Investigation Before Tumor-Associated Lymphocytes Can Be Introduced in Breast Cancer Treatment Algorithm. Journal of Clinical Oncology, 2010, 28, e471-e472.	1.6	7
56	Cellular Adaptive Immune System Plays a Crucial Role in Trastuzumab Clinical Efficacy. Journal of Clinical Oncology, 2010, 28, e369-e370.	1.6	27
57	Intraperitoneal Paclitaxel as Consolidation Treatment in Ovarian Cancer Patients: A Case Control Study. Oncology, 2010, 78, 20-25.	1.9	7
58	Umbilical port site enterocutaneous fistula after laparoscopy for endometrial malignancy. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2010, 149, 119-120.	1.1	0
59	Pain and ovarian endometrioma recurrence after laparoscopic treatment of endometriosis: a long-term prospective study. Fertility and Sterility, 2010, 93, 716-721.	1.0	95
60	GnRH analogue treatment before hysteroscopic resection of submucous myomas: a prospective, randomized, multicenter study. Fertility and Sterility, 2010, 94, 1496-1499.	1.0	95
61	Early prolapse of a neovagina created with self-dilatation and treated with sacrospinous ligament suspension in a patient with Mayer-Rokitansky-Kýster-Hauser syndrome: a case report. Fertility and Sterility, 2010, 93, 267.e1-267.e4.	1.0	33
62	Patient's fertility desire should be taken into consideration in the surgical treatment algorithm of infiltrating endometriosis. Fertility and Sterility, 2010, 93, e3-e4.	1.0	2
63	Dose-dense paclitaxel for advanced ovarian cancer. Lancet, The, 2010, 375, 280.	13.7	1
64	Post radical hysterectomy urinary incontinence: A prospective study of transurethral bulking agents injection. Gynecologic Oncology, 2009, 112, 90-94.	1.4	30
65	HPV induced triple neoplasms: a case report. American Journal of Obstetrics and Gynecology, 2009, 201, e9-e12.	1.3	0
66	Inguinofemoral Lymphadenectomy: Randomized Trial Comparing Inguinal Skin Access Above or Below the Inguinal Ligament. Annals of Surgical Oncology, 2009, 16, 721-728.	1.5	30
67	Vaginal apex necrosis following use of the Frank method of dilation for vaginal agenesis due to Mayerâ€Rokitanskyâ€Kusterâ€Hauser syndrome. International Journal of Gynecology and Obstetrics, 2009, 107, 254-254.	2.3	7
68	Feasibility of the Use of Novel Matrix Hemostatic Sealant (FloSeal) to Achieve Hemostasis during Laparoscopic Excision of Endometrioma. Journal of Minimally Invasive Gynecology, 2009, 16, 153-156.	0.6	44
69	Vaginectomy: A Minimally Invasive Treatment for Cervical Cancer Vaginal Recurrence. International Journal of Gynecological Cancer, 2009, 19, 1625-1631.	2.5	12
70	Three-Day Topotecan Schedule in Heavily Pretreated Recurrent Ovarian Cancer Patients. International Journal of Gynecological Cancer, 2009, 19, 455-459.	2.5	1
71	MAGE-A and NY-ESO-1 expression in cervical cancer: Prognostic factors and effects of chemotherapy. American Journal of Obstetrics and Gynecology, 2008, 198, 99.e1-99.e7.	1.3	40
72	Neoadjuvant chemotherapy followed by radical surgery in patients affected by vaginal carcinoma. Gynecologic Oncology, 2008, 111, 307-311.	1.4	40

#	Article	IF	CITATIONS
73	Urethral Coitus in a Patient with a Microperforate Hymen. Journal of Minimally Invasive Gynecology, 2008, 15, 642-643.	0.6	12
74	Anterior Colporrhaphy Plus Inside-out Tension-free Vaginal Tape for Associated Stress Urinary Incontinence and Cystocele. Journal of Minimally Invasive Gynecology, 2008, 15, 446-451.	0.6	12
75	Late Breast Cancer Recurrence to the Uterine Cervix With a Review of the Literature. International Journal of Gynecological Pathology, 2008, 27, 113-117.	1.4	11
76	RFA strongly modulates the immune system and anti-tumor immune responses in metastatic liver patients. International Journal of Oncology, 2008, 32, 481-90.	3.3	29
77	Vaginoplasty using autologous in vitro cultured vaginal tissue in a patient with Mayer-von-Rokitansky-Kuster-Hauser syndrome. Human Reproduction, 2007, 22, 2025-2028.	0.9	81
78	Hemoglobin variation and blood transfusion rates in patients affected by locally advanced cervical cancer undergoing neo-adjuvant chemotherapy followed by radical surgery: the role of erythropoietic growth factors. Annals of Oncology, 2007, 18, 722-729.	1.2	6
79	A Comparative Analysis of Serum and Serum-free Media for Generation of Clinical Grade DCs. Journal of Immunotherapy, 2007, 30, 567-576.	2.4	26
80	Laparoscopy Compared With Laparoscopically Guided Minilaparotomy for Large Adnexal Masses. Obstetrics and Gynecology, 2007, 110, 241-248.	2.4	42
81	Cancer testis antigen expression in primary and recurrent vulvar cancer: Association with prognostic factors. European Journal of Cancer, 2007, 43, 2621-2627.	2.8	28
82	Minilaparotomy versus laparoscopy in the treatment of benign adnexal cysts: A randomized clinical study. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2007, 133, 218-222.	1.1	19
83	Histologic analysis of endometriomas: what the surgeon needs to know. Fertility and Sterility, 2007, 87, 362-366.	1.0	98
84	Resectoscopic versus bipolar electrode excision of endometrial polyps: a randomized study. Fertility and Sterility, 2007, 87, 909-917.	1.0	33
85	Reply: "An expert forum for the histologic of endometriomas― Fertility and Sterility, 2007, 88, 1018-1019.	1.0	0
86	Laparoscopic-assisted vaginal hysterectomy versus minilaparotomy hysterectomy: A prospective, randomized, multicenter study. Journal of Minimally Invasive Gynecology, 2007, 14, 610-615.	0.6	45
87	CO2 laser therapy of the Bartholin's gland cyst: Surgical data and functional short- and long-term results. Journal of Minimally Invasive Gynecology, 2007, 14, 348-351.	0.6	23
88	Neoadjuvant Chemotherapy Followed by Radical Surgery in Patients Affected by FIGO Stage IVA Cervical Cancer. Annals of Surgical Oncology, 2007, 14, 2643-2648.	1.5	31
89	One-Year Follow-up of Tension-free Vaginal Tape (TVT) and Trans-obturator Suburethral Tape from Inside to Outside (TVT-O) for Surgical Treatment of Female Stress Urinary Incontinence: A Prospective Randomised Trial. European Urology, 2007, 51, 1376-1384. Reply to Francesco Araco et al.a€™s Letter to the Editor re: Marzio Angelo Zullo, Francesco Plotti,	1.9	112
90	Marco Calcagno, Elettra Marullo, Innocenza Palaia, Filippo Bellati, Stefano Basile, Ludovico Muzii, Roberto Angioli and Pierluigi Benedetti Panici. One-Year Follow-up of Tension-free Vaginal Tape (TVT) and Trans-obturator Suburethral Tape from Inside to Outside (TVT-O) for Surgical Treatment of Female Stress Urinary Incontinence: A Prospective Randomised Trial. Eur Urol 2007;51:1376–84. European Urology, 2007, 51, 1454-1455.	1.9	0

6

#	Article	IF	CITATIONS
91	Urologic function and urodynamic evaluation of urinary diversion (Rome pouch) over time in gynecologic cancers patients. Gynecologic Oncology, 2007, 107, 200-204.	1.4	6
92	An update in neoadjuvant chemotherapy in cervical cancer. Gynecologic Oncology, 2007, 107, S20-S22.	1.4	34
93	Neoadjuvant chemotherapy plus radical surgery in locally advanced cervical cancer during pregnancy: a case report. American Journal of Obstetrics and Gynecology, 2007, 197, e5-e6.	1.3	69
94	Secondary Cytoreductive Surgery in Patients with Platinum-Sensitive Recurrent Ovarian Cancer. Annals of Surgical Oncology, 2007, 14, 1136-1142.	1.5	82
95	Mechanical bowel preparation before gynecologic laparoscopy: a randomized, single-blind, controlled trial. Fertility and Sterility, 2006, 85, 689-693.	1.0	62
96	Splenectomy During Secondary Cytoreduction for Ovarian Cancer Disease Recurrence: Surgical and Survival Data. Annals of Surgical Oncology, 2006, 13, 1717-1723.	1.5	29
97	Distal phalange necrosis: A severe manifestation of palmar plantar erythrodysesthesia. American Journal of Obstetrics and Gynecology, 2006, 195, e1-e2.	1.3	7
98	Ovarian cancer, diagnosed with PET, with bilateral inguinal lymphadenopathy as primary presenting sign. Gynecologic Oncology, 2006, 100, 621-622.	1.4	12
99	Solitary gastric recurrence from ovarian carcinoma: A case report and literature review. Surgical Oncology, 2006, 15, 267-270.	1.6	7
100	Single agent cisplatin chemotherapy in surgically resected vulvar cancer patients with multiple inguinal lymph node metastases. Gynecologic Oncology, 2005, 96, 227-231.	1.4	50
101	Laparoscopic stripping of endometriomas: a randomized trial on different surgical techniques. Part II: pathological results. Human Reproduction, 2005, 20, 1987-1992.	0.9	127
102	Laparoscopic stripping of endometriomas: a randomized trial on different surgical techniques. Part I: Clinical results. Human Reproduction, 2005, 20, 1981-1986.	0.9	70
103	Ringer's lactate solution remains in the peritoneal cavity after laparoscopy longer than expected. Fertility and Sterility, 2005, 84, 148-153.	1.0	11
104	TRANSURETHRAL POLYDIMETHYLSILOXANE IMPLANTATION: A VALID OPTION FOR THE TREATMENT OF STRESS URINARY INCONTINENCE DUE TO INTRINSIC SPHINCTER DEFICIENCY WITHOUT URETHRAL HYPERMOBILITY. Journal of Urology, 2005, 173, 898-902.	0.4	37
105	Ultrasonographic Evaluation of Postoperative Ovarian Cyst Formation after Laparoscopic Excision of Endometriomas. Journal of Minimally Invasive Gynecology, 2004, 11, 457-461.	1.2	5
106	Guidelines of how to manage vesicovaginal fistula. Critical Reviews in Oncology/Hematology, 2003, 48, 295-304.	4.4	145